# | Title | Journal | Year | Citations |
---|
1 | Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations | Prostate | 1983 | 974 |
2 | Family history and the risk of prostate cancer | Prostate | 1990 | 609 |
3 | Molecular characterization of human prostate carcinoma cell lines | Prostate | 2003 | 555 |
4 | The zonal anatomy of the prostate | Prostate | 1981 | 521 |
5 | Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer | Prostate | 2004 | 475 |
6 | Etiology and disease process of benign prostatic hyperplasia | Prostate | 1989 | 453 |
7 | Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation | Prostate | 1993 | 407 |
8 | Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model | Prostate | 2003 | 402 |
9 | The TNM classification of prostate cancer | Prostate | 1992 | 383 |
10 | Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers | Prostate | 1986 | 367 |
11 | PC3 is a cell line characteristic of prostatic small cell carcinoma | Prostate | 2011 | 365 |
12 | Distribution of metastatic sites in patients with prostate cancer: A population‐based analysis | Prostate | 2014 | 352 |
13 | Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen | Prostate | 1996 | 337 |
14 | Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement | Prostate | 1987 | 330 |
15 | LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis | Prostate | 2000 | 328 |
16 | Antagonistic effect of androgen on prostatic cell death | Prostate | 1984 | 327 |
17 | Radiation therapy for carcinoma of the prostate | Prostate | 1981 | 324 |
18 | The prostate: An increasing medical problem | Prostate | 1990 | 321 |
19 | Prostate antigen: A new potential marker for prostatic cancer | Prostate | 1981 | 319 |
20 | Increased Nox1 and hydrogen peroxide in prostate cancer | Prostate | 2005 | 309 |
21 | New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens | Prostate | 1983 | 305 |
22 | Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients | Prostate | 1996 | 294 |
23 | Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo | Prostate | 2001 | 292 |
24 | Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy | Prostate | 2011 | 287 |
25 | High-grade prostate cancer is associated with low serum testosterone levels | Prostate | 2001 | 280 |
26 | Androgen deprivation therapy for prostate cancer: Current status and future prospects | Prostate | 2004 | 279 |
27 | p53 oncogene mutations in three human prostate cancer cell lines | Prostate | 1993 | 276 |
28 | Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer | Prostate | 2011 | 273 |
29 | Structural heterogeneity and protein composition of exosome‐like vesicles (prostasomes) in human semen | Prostate | 2009 | 271 |
30 | Regulation of prostatic growth and function by peptide growth factors | Prostate | 1996 | 269 |
31 | Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer | Prostate | 1998 | 269 |
32 | Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial | Prostate | 1999 | 262 |
33 | Androgen-repressed messages in the rat ventral prostate | Prostate | 1986 | 254 |
34 | Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration | Prostate | 1989 | 246 |
35 | Transrectal ultrasound in the diagnosis of prostate cancer: Location, echogenicity, histopathology, and staging | Prostate | 1985 | 243 |
36 | Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignancies | Prostate | 2010 | 241 |
37 | TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients | Prostate | 2011 | 239 |
38 | Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer | Prostate | 2010 | 233 |
39 | The proliferative function of basal cells in the normal and hyperplastic human prostate | Prostate | 1994 | 231 |
40 | CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12 | Prostate | 2006 | 229 |
41 | Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway | Prostate | 2000 | 228 |
42 | Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis | Prostate | 2009 | 227 |
43 | Proteomic analysis of human prostasomes | Prostate | 2003 | 226 |
44 | Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion | Prostate | 2006 | 225 |
45 | High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer | Prostate | 2011 | 224 |
46 | Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: Apoptotic bodies, microvesicles, and exosomes | Prostate | 2014 | 223 |
47 | Mechanisms of constitutive NF-κB activation in human prostate cancer cells | Prostate | 2002 | 221 |
48 | Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer | Prostate | 2002 | 220 |
49 | LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics | Prostate | 2017 | 219 |
50 | Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low‐risk, localized prostate cancer | Prostate | 2013 | 217 |